Next-generation upgrade strengthens data comparability and compliance—without changing trusted instrumentation
San Jose – (Sep 2, 2026) – Beckman Coulter Life Sciences, a Danaher company and a global leader in laboratory automation and innovation, today announced the launch of Vi-CELL BLU 2.0 Viability Analyzer Software, a major upgrade that enables laboratories to modernize cell viability workflows while maintaining data continuity, compliance and operational confidence. The new software supports laboratories in solving complex cell analysis challenges and accelerating the transition from research to biomanufacturing.
Built on the trusted Vi-CELL BLU instrument, the Vi-CELL BLU 2.0 Viability Analyzer Software delivers enhanced data comparability, integrity and uptime, enabling R&D and manufacturing teams to modernize workflows without disrupting established processes.
By offering improved cell counting algorithms and configurable analysis settings designed to align results with legacy instruments, supported by validated software documentation and application guidance, Vi-CELL BLU 2.0 Software helps labs avoid the complexity of an equipment transition.
“Vi-CELL BLU 2.0 Viability Analyzer Software was developed to help laboratories modernize cell analysis workflows without compromising data integrity or compliance,” said Dave Kremer, Senior Director Cell Health and Centrifugation at Beckman Coulter Life Sciences. “By aligning results with legacy systems while introducing advanced data controls, we’re enabling customers to accelerate adoption with confidence and reduce risk during transition.”
Additional enhancements include role-based access controls, electronic signatures, audit trails and traceability features to support regulated workflows and streamline integration into GMP environments, ensure consistency across projects, users and sites.
This advancement reflects Beckman Coulter Life Sciences commitment to accelerating scientific innovation and enabling more reliable, scalable cell analysis across the biopharma workflow.
About Vi-CELL BLU Cell Viability Analyzer
The Vi-CELL BLU Cell Viability Analyzer is a fully automated system that performs cell counting and viability analysis using the widely accepted trypan blue dye exclusion method. Designed to reduce manual handling and operator variability, the system supports fast, reproducible measurements with strong instrument-to-instrument correlation and automation-ready connectivity. Visit the link to explore how Vi-CELL BLU 2.0 Software supports compliant cell analysis workflows.
About Beckman Coulter Life Sciences
Time is the most critical facet in the laboratory today: time to get life-saving therapies to patients faster; reclaiming time by automating tedious manual workflows; and saving time otherwise spent addressing erroneous or complex results.
At Beckman Coulter Life Sciences, a Danaher company, we are partners in time. We accelerate answers to critical questions through the power of efficiency, saving hours from some workflows and delivering reliable results in centrifugation, flow cytometry, genomic solutions, particle analysis/counters, and liquid handlers.
We develop innovations for scientists by scientists, with many of our 3,300+ global colleagues coming from the laboratory with a deep understanding of today’s challenges and complexities. We’re passionate about translating science in partnership with our customers, and our customizable, accessible and sustainable solutions empower them with intuitive workflow efficiencies.
Time and again customers put their trust in us, with 400,000+ of our built-to-last products currently delivering results in labs worldwide—all backed by our dependable service and application experts offering educational insights and tailored support.
It’s all part of our time-tested approach since 1935 to bring meaningful innovations at the speed of life—and we’re just beginning. Working together, let’s advance human health for a better tomorrow!
Get to know us by clicking here and by following us on LinkedIn.
About Danaher
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com.
Media Contact:
Amber Smock,
Marketing Communications Manager
[email protected]
2026-GBL-EN-109526-v1
